Exelixis, Inc.
EXEL
Classificação em ações
#1383
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Preço da ação
$64.01
Última sincronização: 2026-10-20
Valor de mercado
$16.09B
Variação (1 dia)
2.11%
Variação (1 ano)
77.15%
País
US
Negociar Exelixis, Inc. (EXEL)
Categoria
Healthcare
Rácio P/E de Exelixis, Inc. (EXEL)
Rácio P/E em October 2026 TTM: 18.54
De acordo com os últimos relatórios financeiros e o preço das ações da Exelixis, Inc., o rácio P/E atual (TTM) é 18.54. No final de 2025, a empresa tinha um P/E de 18.90.
Histórico do rácio P/E da Exelixis, Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 18.54 | -1.92% |
| 2025 | 18.90 | -48.55% |
| 2023 | 36.74 | 29.84% |
| 2022 | 28.29 | 13.57% |
| 2021 | 24.91 | 55.37% |
| 2020 | 16.03 | 91.06% |
| 2018 | 8.39 | -85.50% |
| 2017 | 57.87 | -208.79% |
| 2016 | -53.19 | 5,005.52% |
| 2014 | -1.04 | -77.39% |
| 2013 | -4.61 | -5.78% |
| 2012 | -4.89 | -162.05% |
| 2011 | 7.88 | -181.69% |
| 2010 | -9.65 | 185.36% |
| 2009 | -3.38 | -66.78% |
| 2007 | -10.18 | 32.57% |
| 2006 | -7.68 | -12.69% |
| 2005 | -8.80 | 75.26% |
| 2004 | -5.02 | 3.18% |
| 2003 | -4.86 | -7.50% |
| 2002 | -5.26 | -51.55% |
| 2001 | -10.85 | 80.10% |
| 2000 | -6.03 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 28.78 | 55.26% |
US
|
|
| -28.36 | -252.97% |
US
|
|
| -24.57 | -232.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 63.61% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.